Targacept Initiates New Studies of Anti-Inflammatory Drug

Targacept announced Wednesday it was launching Phase 2 clinical trials of its TC-6987 compound that could be used to treat asthma and Type 2 diabetes.

Targacept has announced its initriation of  two separate Phase II studies of its TC-6987 product candidate, one in patients with asthma and one in patients with type II diabetes. It is hoped that the trials will help to guide the selection of the therapeutic indications for which TC-6987 is best suited for later-stage development.

The Phase II study in asthma is a multicentre, double-blind, placebo-controlled, randomised and parallel-group trial, which is being conducted in the US.

The study will enrol approximately 90 adults with mild-to-moderate asthma, who will be randomised to receive either TC-6987 or a placebo. The study will also assess safety, tolerability and pharmacokinetics of TC-6987.